At NETA, we hold health promotion at the highest regard—placing the well-being of individuals affected by epilepsy at the forefront of everything we do. We are a global, volunteer-led initiative focused on transforming the landscape of rare and complex epileptic disorders, including Dravet Syndrome, Temporal Lobe Epilepsy, KBG Syndrome, and Abdominal Epilepsy.
With a foundation in cutting-edge transcriptomic research and bioinformatics, NETA bridges the gap between scientific innovation and community impact. Our team of researchers, clinicians, and advocates work collaboratively to improve early diagnosis, enable personalized treatment pathways, and promote education and awareness across borders.
We are committed to empowering families, supporting clinicians, and elevating the voices of those living with rare forms of epilepsy—through research, outreach, and a shared mission to foster a healthier, more informed future for all.
Company Details
- Employees
- 29
- Founded
- -
- Address
- Sydney, Nsw 2000, Au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- SWAN Genomics.
- HQ
- Sydney, NSW
Neta Discovery Questions
Neta Discovery's LinkedIn profile is https://au.linkedin.com/company/n-e-t-a
Neta Discovery has
29 employees.
View email and phone details for 29
employees at Neta Discovery.
Neta Discovery's industry is
Biotechnology Research
Neta Discovery's top competitors are
Inventia Life Science,
Garvan Institute Of Medical Research,
Mensa France,
Austech Medical Laboratories,
Swan Genomics,
Synaptic Unity,
Medisha.com,
Edna Biolabs Private Limited,
Epiminder,
Neta Research Academy.
Neta Discovery's categories are Biotechnology Research
Neta Discovery's founding year is 2023
